<div>
<h2>Key Points</h2><ul><li>Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million.</li><li>Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales and price changes.</li><li>The trade represented a 2.6% change in reportable 13F assets under management.</li><li>The move marked a full exit from OCUL; the position was previously 3.4% of the fund's AUM.</li><li>10 stocks we like better than Ocular Therapeutix ›</li></ul><p>On May 15, 2026, Saturn V Capital Management disclosed a full exit from <strong>Ocular Therapeutix</strong> <span class="ticker">(NASDAQ:OCUL)</span>, selling 1,504,880 shares in a trade estimated at $14.34 million based on quarterly average pricing.</p><h2 id="what-happened">What happened</h2><p>According to an SEC filing dated May 15, 2026, Saturn V Capital Management sold its entire 1,504,880-share holding in Ocular Therapeutix. The estimated transaction value was $14.34 million, calculated using the average closing price for the first quarter of 2026. The fund's reported position in the stock fell to zero, with a quarter-end valuation shift of $18.27 million reflecting both trading and market price movement.</p><h2 id="what-else-to-know">What else to know</h2><ul><li>Saturn V Capital Management fully exited Ocular Therapeutix.</li><li>Top holdings after the filing:<ul><li>NASDAQ: ALMS: $70.54 million (12.8% of AUM)</li><li>NASDAQ: AMLX: $60.46 million (10.9% of AUM)</li><li>NASDAQ: ABVX: $60.43 million (10.9% of AUM)</li><li>NASDAQ: PCVX: $47.91 million (8.7% of AUM)</li><li>NASDAQ: PHVS: $33.94 million (6.1% of AUM)</li></ul></li><li>As of Tuesday, shares of Ocular Therapeutix were priced at $8.06, up 7% over the past year, compared to a 24% gain for the S&amp;P 500.</li></ul><h2 id="company-overview">Company Overview</h2><section><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Price (as of market close 2026-05-14)</td><td>$8.06</td></tr><tr><td>Market Capitalization</td><td>$1.8 billion</td></tr><tr><td>Revenue (TTM)</td><td>$52.04 million</td></tr><tr><td>Net Income (TTM)</td><td>($290.50 million)</td></tr></tbody></table></section><h2 id="company-snapshot">Company Snapshot</h2><ul><li>Ocular Therapeutix develops and commercializes ophthalmic therapies, including marketed products such as ReSure Sealant and DEXTENZA, and maintains a pipeline of drug delivery implants for retinal, glaucoma, and dry eye diseases.</li><li>The company generates revenue primarily from product sales and strategic collaborations, leveraging proprietary hydrogel-based sustained-release technology for both device and pharmaceutical applications.</li><li>The company’s products are used in the treatment of ocular inflammation, pain, retinal diseases, and glaucoma.</li></ul><p>Ocular Therapeutix is a biopharmaceutical company with a focus on innovative drug delivery solutions for ophthalmic diseases. The company combines proprietary hydrogel technology with established and novel therapeutics, aiming to address unmet medical needs in eye care. Strategic collaborations and a diversified pipeline position Ocular Therapeutix to compete in the growing market for advanced ophthalmic therapies.</p><h2 id="what-this-transaction-means-for-investors">What this transaction means for investors</h2><p>Ocular shares have really struggled in recent months, including since the latest earnings report earlier this month, when revenue came in lighter than investors hoped and losses widened as spending ramped aggressively ahead of potential commercialization.<br/><br/>That said, the underlying business still has some momentum. Earlier this year, Ocular reported positive Phase 3 SOL-1 data for AXPAXLI in wet AMD, including what it called the first successful superiority study against an approved anti-VEGF therapy. The company also said its SOL-R Phase 3 trial remains on track for topline data in early 2027.<br/><br/>Financially, though, the story got more complicated. First-quarter revenue rose less than 1% to $10.8 million, while research and development expenses jumped to $66.2 million from $42.9 million a year earlier. Net losses widened to $88.6 million.<br/><br/>Ultimately, long-term investors should remember that short-term skepticism matters less than long-term execution. Ocular still has a sizable $666.7 million cash balance and runway into 2028. Now, the market wants proof that the company can convert promising clinical data into a commercially viable retina franchise.</p><h2>Should you buy stock in Ocular Therapeutix right now?</h2>
<p>Before you buy stock in Ocular Therapeutix, consider this:</p>
<p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Ocular Therapeutix wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $483,476</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,362,941</strong>!*</p>
<p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 998<span>% — a market-crushing outperformance compared to 207% for the S&amp;P 500. <strong><span>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</span></strong></span></p>
<p>See the 10 stocks »</p>
<p style="color: #767676; text-align: left"><em>*Stock Advisor returns as of May 19, 2026. </em></p><p><em>Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.</em></p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

OCUL

LABU

SBIO

<p>Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1,504,880 shares for an estimated $14.34 million. The fund's reported assets fell by $18.27 million due to share sales and price changes. Ocular's recent performance has been mixed, with revenue growth lagging and net losses widening, despite positive clinical trial data. Investors are advised to consider other stocks, as Ocular was not included in a recent top investment list.</p>

nasdaq

Ocular Therap

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Alumis

Amylyx Pharmaceuticals

Abivax SA

Vaxcyte

Pharvaris BV

S&P 500

Netflix

NVIDIA

NVIDIA Corporation

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors